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Paclitaxel-induced neuropathic pain (PINP) is a dose-limiting side eﬀect that largely aﬀects the patient’s quality
of life and may limit the use of the drug as a chemotherapeutic agent for treating metastatic breast cancer and
other solid tumors. Recently, a putative role for the gaseous mediator hydrogen sulﬁde (H2S) in nociception
modulation has been suggested. The aim of the present study was to investigate the potential eﬃcacy of the slow
release H2S donor GYY4137 to alleviate and prevent PINP. Female BALB/c mice that were intraperitoneally (i.p.)
injected with paclitaxel (2 mg/kg) for 5 consecutive days developed thermal hyperalgesia, cold and mechanical
allodynia and had reduced of H2S, generation in the spinal cord and paw skin. Treatment of mice with established thermal hyperalgesia with GYY4137 or the analgesic positive control drug gabapentin produced antihyperalgesic activities. The antihyperalgesic activity of GYY4137 was antagonized by the ATP sensitive potassium channels (KATP channels) blocker glibenclamide. Co-treatment with GYY4137 and paclitaxel prevented
the paclitaxel-induced decrease in H2S, generation as well as the paclitaxel-induced thermal hyperalgesia, cold
allodynia and mechanical allodynia. GYY4137 enhanced paclitaxel's anti-proliferative eﬀects against the breast
cancer cell line MCF-7. The present results suggest that GYY4137 alleviates paclitaxel-induced thermal hyperalgesia, via KATP channels. GYY4137 prevents PINP possibly by blocking the paclitaxel-induced reduction in the
generation of H2S, in the tissues, while enhancing the anti-cancer activity of paclitaxel, and therefore warrants
further research as a candidate for prevention of PINP in clinical settings.

1. Introduction
Platinum analogues (cisplatin and oxaliplatin), taxanes (paclitaxel),
vinca alkaloids (vincristine) and proteasome inhibitors (bortezomib)
are the most common antineoplastic drugs successfully employed as
ﬁrst-line treatment for several solid and blood cancers, including breast,
lung, colorectal, gastric cancers and multiple myeloma. Although these
compounds have diﬀerent chemical structures and mechanisms of action, they all induce the development of chemotherapy-induced neuropathic pain (CINP) as a common side eﬀect. Some of the symptoms of
neuropathic pain include hyperalgesia (an increased response to normally painful stimuli), allodynia (pain triggered by normally nonpainful stimuli, such as cloth rubbing against the skin) and spontaneous
sensations such as burning, shooting, numbness, spasm and prickling
[1,2]. These symptoms can have a serious negative impact on the
psychosocial well-being and overall quality of life of the patient. Unfortunately, there are no clinically proven eﬀective drugs for the prevention of CINP. A variety of therapeutic agents are used to relieve
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patients with CINP [3], but currently only duloxetine has moderate
recommendation for the treatment of CINP [4,5]. The gaseous signaling
molecule hydrogen sulﬁde (H2S) has recently been proposed to play a
role as neuromodulator and cytoprotective mediator in several tissues,
including the cardiovascular and nervous system [6–8]. A putative role
for H2S in nociception modulation has been suggested. For example,
inhaled H2S has been shown to prevent the neuropathic pain behavior
induced by chronic constriction injury of the sciatic nerve in mice [9]
and rats [10]. Moreover, H2S-releasing analgesic compounds have been
shown to exert greater potency against diﬀerent forms of pain [11].
Furthermore, H2S has been shown to induce mu opioid receptor-dependent analgesia in a rodent model of visceral pain [12]. A recent
study showed a role of H2S donors in relieving established CINP possibly via activation of voltage-gated Kv7potassium channels [13],
however whether there are changes in H2S during CINP, H2S donors can
prevent the development of CINP or other potassium channels play a
role in the activity of H2S donors against CINP remains to be identiﬁed.
The aims of this study were therefore to evaluate the whether GYY4137
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with normal saline in the same proportion as the paclitaxel solution,
thus, constituted of about 1.7 % Cremophor EL and 1.7 % ethanol in
normal saline. Paclitaxel (2 mg/kg) or its vehicle was administered to
mice intraperitoneally (i.p.), in a volume of 10 mL/kg, once daily for 5
consecutive days. This treatment regimen has been reported to produce
painful neuropathy and thermal hyperalgesia in mice [17–19]

can prevent the development of PINP and alleviate established paclitaxel-induced thermal hyperalgesia (therapeutic regimen), whether
KATP channels are involved in the antihyperalgesic eﬀect of GYY4137,
and whether there are changes in H2S levels or generation capacity in
tissues during PINP.
2. Materials and methods

2.4. Animal groups and treatment regimens
2.1. Drugs and chemicals
2.4.1. Acute (therapeutic) regimen
Mice were treated i.p. with GYY4137 (25, 50 and 100 mg/kg), gabapentin (10 mg/kg), used as an analgesic positive control as described
previously [20],or vehicle once on day 7 after ﬁrst administration of
paclitaxel, when the mice had developed thermal hyperalgesia as previously described [17]. Reaction latencies to the hot plate test were
measured before drug treatment (two baseline values) and at 0.5, 1,
1.5, 2, and 3 h post drug treatment.

Paclitaxel was purchased from Tocris Bioscience (Cat. No. 1097;
Bristol, UK), and all other drugs were purchased from Sigma Aldrich, St.
Louis, MO, except GYY4137 which was synthesized in-house, as described by Li et al. [15]. Structural characterization by spectrometric
methods was performed by The General Facilities Science (GF-S), Faculty of Science, Kuwait University, Kuwait. Brieﬂy, GYY4137 was
synthesized as follows: Morpholine (40 mmol) in anhydrous dichloromethane (DCM, 12 mL) was added dropwise to a solution of
Lawesson’s reagent (8.0 mmol) in anhydrous DCM (12 mL) under nitrogen gas at room temperature and the reaction mixture was stirred for
2 h. The resulting precipitate was collected by suction ﬁltration and
washed several times with anhydrous DCM and dried to give a pure
white solid product (66 % yield; melting point 156−159 °C). After
synthesis, the purity and structure of the product were veriﬁed using
Proton Nuclear Magnetic Resonance Spectrometry (1H NMR) and Mass
Spectrometry. GYY4137 was analyzed by 1H-NMR spectrum in CHCl3d3 recorded on a Bruker Avance II 600 NMR spectrometer using solvent
peak as a reference signal, and the Mass spectrum was recorded on a
Waters QToF high resolution / Mass Spectrometer (LC–MS/MS High
resolution). 1H-NMR (600 MHz; (CDCl3): δ 2.94–2.97 (4H, broad apparent q, J =6.0 Hz, N(CH2)2 for morpholine attached to P), 3.19 (4H,
broad t, J =4.9 Hz, morpholinium (CH2)2N), 3.59 (4H, broad t, J =4.3
Hz, O(CH2)2 for morpholine attached to P), 3.74 (4H, broad t, J =4.90
Hz, morpholinium (CH2)2O), 3.82 (3H, s, CH3O), 5.28 ("1H", s, 0.5
CH2Cl2), 6.87–6.89 (2H, m, arylC-H o-to OCH3) and 8.15−8.05 (2H, m,
arylC-H o-to P). 9.19 (2H, broad signal, morpholinium +NH2). HRMS
(m/z, ES+): Calcd for C15H25N2O3PS2 376.1044; found 377.1100 (M+
+ H).

2.4.2. Chronic (prophylactic) regimen
GYY4137 50 mg/kg was co-administered with paclitaxel daily for 5
days. The mice were assessed for the development of PINP using the hot
and cold plate tests and dynamic plantar aesthesiometer.
2.5. Assessment of thermal nociception
For thermal hyperalgesia assessment, animals were individually
placed on a hot-plate (Panlab S.L., Barcelona, Spain) with the temperature adjusted to 55 ± 1 °C. The latency to the ﬁrst sign of paw
licking, vocalization or jump response to avoid the heat was taken as an
index of pain threshold. Reduction in paw licking or jump response time
latency (RTL) indicates hyperalgesia, whereas an increase in RTL after
drug treatment indicates antinociceptive activity of the drug. Reaction
latencies to hot plate test were measured before (baseline latency), at
day 7 after ﬁrst injection of paclitaxel, and at various time points after
drug treatment. A cut-oﬀ period of 20 s was maintained to avoid damage to the paws. For thermal allodynia test, animals were individually
placed on a cold-plate with the temperature adjusted to 4 ± 1 °C. The
latency to the ﬁrst sign of paw licking was taken as an index of pain
threshold. Reduction in paw licking RTL indicates allodynia, whereas
an increase in RTL after drug treatment indicates antinociceptive activity of the drug. A cut-oﬀ period of 60 s was maintained to avoid
damage to the paws.

2.2. Animals and ethics statements
Female BALB/c mice (8–12 weeks old), weighing approximately
20−30 g, supplied by the Animal Resource Center (ARC) at the Health
Sciences Center, Kuwait University were used in this study. All animals
were housed under optimal laboratory conditions, maintained on a
natural light and dark cycle and had free access to food and water ad
libitum. Animals were acclimatized to laboratory conditions before any
tests. All experimental procedures were carried out in strict accordance
with the recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health (NIH
Publication number 85−23, Revised 1985) as approved by the Animal
Welfare and Ethics Committees of Kuwait University. Animals were
handled in compliance with ethical guidelines for research in experimental pain with conscious animals [15], and all eﬀorts were made to
minimize suﬀering. Whenever possible, animal studies are reported in
accordance with ARRIVE guidelines [16].

2.6. Assessment of mechanical allodynia
Mechanical allodynia in mice was measured using the dynamic
plantar aesthesiometer (Ugo Basile, Italy). Brieﬂy, mice were left to
habituate for 30 min inside plastic enclosures on top of a perforated
platform before starting a microprocessor which was programmed to
automatically lift a metal ﬁlament that exerted a linearly increasing
force (0.25 g/s with cut-oﬀ time of 20 s) on the hind paw. A stop signal
was automatically attained, either when the animal removed the paw or
at the cut-oﬀ force of 5 g. Withdrawal thresholds in response to the
mechanical stimulus were automatically recorded in grams. The hind
paws were tested at least 3 times. The baseline mechanical threshold
was assessed one day before the induction of the neuropathic pain.

2.3. Induction of neuropathic pain by paclitaxel administration
2.7. Involvement of ATP sensitive potassium channel (KATP channel)
Peripheral painful neuropathy was induced in mice by intraperitoneal (i.p.) administration of paclitaxel as previously described
[17]. Paclitaxel was dissolved in a solution made up of 50 % Cremophor
EL and 50 % absolute ethanol to a concentration of 6 mg/ml (stored at
−20 °C, for a maximum of 14 days) and then diluted in normal saline
(NaCl 0.9 %) to a ﬁnal concentration of 0.2 mg/ml just before administration. The vehicle for paclitaxel was diluted at the time of injection

To explore the possible contribution of KATP channel in the antinociceptive eﬀect of GYY4137, mice with paclitaxel-induced neuropathic pain were pre-treated with glibenclamide (an ATP-sensitive K +
channel inhibitor) 15 min before the injection of either vehicle, or
GYY4137 (50 mg/kg, i.p.). The reaction latencies to the hot plate were
recorded at 2 h after injection of GYY4137 or vehicle.
2
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computed) where within each row, columns were compared (simple
eﬀects within each row) i.e. compared each cell mean with every other
cell mean on that row. The diﬀerences were considered signiﬁcant
when p < 0.05. The results were expressed as the mean ± standard
error of the mean (S.E.M).

2.8. Measurement of plasma H2S level
H2S levels were determined by zinc trapping spectrophotometric
assay [14]. Blood samples were collected by cardiac puncture under
terminal anesthesia and plasma was separated. The initial reaction
mixture was made by mixing 50 μl plasma with 200 μl of 1 % zinc
acetate. Then, 200 μl of N,N-dimethyl-p-phenylenediamine sulfate (20
mM in 7.2 M HCl) and 200 μl of FeCl3 (30 mM in 1.2 M HCl) were
added. After 10-minute incubation, the absorbance of the reaction
mixture was measured at 670 nm, and H2S concentration was calculated against a standard curve of NaHS solution (25−200 μM).

3. Results
3.1. GYY4137 alleviates established paclitaxel-induced thermal
hyperalgesia in an ATP sensitive potassium channel (KATP channel)dependent manner

2.9. Measurement of H2S tissue synthesizing activity

At the baseline day (day 0), there were no signiﬁcant diﬀerences in
the withdrawal latencies to heat-stimuli between the animal groups.
Paclitaxel-treated mice had signiﬁcant reduction in RTL (thermal hyperalgesia) in the hot plate test on day 7 after ﬁrst drug administration
compared to the baseline (pretreatment) latency (Fig. 1A; p < 0.05).
Therefore, paclitaxel-treated mice developed thermal hyperalgesia on
day 7 after ﬁrst administration of paclitaxel, in agreement with previous evidence [17]. The positive analgesic control drug gabapentin (10
mg/kg) produced antihyperalgesic eﬀect starting after 1.5 h of treatment, i.e. signiﬁcantly increasing RTL to 5.2 ± 0.2 s, as compared to
3.6 ± 0.2 s for paclitaxel + vehicle group (n = 6; p < 0.05, Fig. 1A).
The antihyperalgesic eﬀect of gabapentin was from 1.5 to 3 h, reached a
peak level after 2 h (RTL 6.1 ± 0.2 s vs. 3.6 ± 0.2 s for paclitaxel +
vehicle group; n = 6; p < 0.01, Fig. 1A). Treatment with GYY4137
produced antihyperalgesic eﬀects with all the tested doses but with
variable start and peak times. A 25 mg/kg dose of GYY4137 produced a
signiﬁcant antihyperalgesic eﬀect from 1.5 to 3 h after treatment, as
evident by the increased RTL to 5.4 ± 0.1 s (n = 8) compared to
3.5 ± 0.2 s for paclitaxel + vehicle group at 1.5 h and 5.5 ± 0.4 (n =
8) compared to 3.7 ± 0.2 s for paclitaxel + vehicle group (n = 6) at 3 h
(p < 0.01; Fig. 1A) and reached a peak at 2 h (RTL 6.8 ± 0.2 s, n = 8
vs. 3.6 ± 0.2, n = 6 paclitaxel + vehicle-treated mice; p < 0.001;
Fig. 1A). A 50 mg/kg dose of GYY4137 produced antihyperalgesic effect from 1 to 2 h; RTL of 5.2 ± 0.3 s (n = 8) compared to 3.4 ± 0.3 s
(n = 6) for paclitaxel + vehicle-treated mice (p < 0.05; Fig. 1A) at 1 h,
and peaked and ended at 2 h with RTL of 7.1 ± 0.1 s (n = 8) compared
to 3.6 ± 0.2 s (n = 6) for paclitaxel + vehicle-treated mice (p < 0.01;
Fig. 1). The highest tested GYY4137 dose (100 mg/kg) also signiﬁcantly
increased the RTL compared to paclitaxel + vehicle-treated mice from
1 to 4 h (when the experiment was terminated): RTL 5.1 ± 0.2 s (n = 8)
vs. 3.4 ± 0.3 s for paclitaxel + vehicle-treated mice (n = 6) at 1 h
(p < 0.05; Fig. 1A), peaked at 3 h (RTL 7.2 ± 0.3 s, n = 8 vs. 3.7 ± 0.2,
n = 6, respectively; p < 0.01; Fig. 1), and remained signiﬁcantly high
until 4 h (RTL 4.7 ± 0.2 s, n = 8 vs. 3.1 ± 0.3, n = 6, respectively;
p < 0.01; Fig. 1A). A signiﬁcant diﬀerence was observed in the therapeutic eﬀects of gabapentin 10 mg/kg and GYY4137 100 mg/kg only
against paclitaxel-induced thermal hyperalgesia at 3 h (RTL 5.8 ± 0.4 s,
n = 8 for gabapentin 10 mg/kg vs. 7.2 ± 0.3, n = 6 for GYY4137 100
mg/kg; p < 0.05). The other diﬀerence was in the starting time of induction of antihyperalgesic eﬀect, as GYY4137 100 mg/kg induced its
antihyperalgesic action earlier (after 1 h) than gabapentin (after 1.5 h),
and the eﬀect was sustained for a longer time (up to 4 h) for GYY4137
compared to 3 h only with gabapentin 10 mg/kg (Fig. 1A).
The optimal time point (2 h) and dose (50 mg/kg) for GYY4137
analgesic activity were selected based on the results from the dose- and
time-response experiment depicted in Fig. 1. The administration of the
KATP channel antagonist glibenclamide (10 mg/kg) to mice with paclitaxel-induced thermal hyperalgesia did not alter the reaction latency
to hot-plate test compared to vehicle-treated mice (p > 0.05; Fig. 1B).
However, treatment with glibenclamide signiﬁcantly attenuated the
antihyperalgesic eﬀect of GYY4137 in the mice, i.e. a 37 % reduction in
reaction latency from 8.1 ± 0.3 s for paclitaxel + GYY4137 to
5.2 ± 0.1 s for paclitaxel + GYY4137 + glibenclamide (p < 0.01;
Fig. 1B). This result reveals that the acute antihyperalgesic action of

Enzymatic H2S synthesis in tissue homogenates was measured by
zinc trapping spectrophotometric assay as described previously [14]
with slight modiﬁcation. Supernatant derived from the tissue homogenates (430 μl) was incubated with 20 μl pyridoxal 5′-phosphate (PLP,
2 mM) and the substrate L-cysteine (20 μl, 10 mM) and sealed with a
double paraﬁlm layer to avoid leakage of H2S gas generated after incubating the tube in a 37 °C water bath for 45 min. Baseline controls
that contained trichloroacetic acid (TCA; 10 % w/v, 250 μl) were prepared in parallel to obtain the basal H2S background level. At the end of
the incubation period, zinc acetate (1% w/v, 250 μl) was injected to
trap the H2S followed by TCA (10 % w/v, 250 μl) to terminate the
reaction. Subsequently, N,N-dimethylp-phenylenediamine sulfate dye
(NNDPD; 20 mM, 133 μl) in 7.2 M HCl was added, followed by the
addition of FeCl3 (30 mM,133 μl) in 1.2 M HCl. After centrifugation
(14,000 rpm for 4 min at 4 °C), absorbance (670 nm) of the resulting
methylene blue in the supernatant was measured using a 96-well microplate reader (Tecan Systems Inc., CA, USA) and compared against a
standard curve of NaHS (concentrations ranging from 3.125–250 μM).
At least 3 biological samples were assayed in duplicate and results were
expressed as nmol H2S formed per mg protein. Protein level in each
homogenate was estimated using Bradford assay (Bio-Rad, CA, USA).
2.10. Anti-proliferative activity of GYY4137 and paclitaxel against breast
cancer cell lines
Human breast carcinoma cell line MCF-7 (American Type Culture
Collection, VA, USA) were seeded in a 24 well plate (∼104), allowed to
attach overnight and treated after 24 and 72 h with vehicle (DMSO),
various concentrations of paclitaxel (1 nM to 100 μM), GYY4137 (1 nM
to 100 μM) or a combination of both drugs. Growth was assessed by
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]
assay (Promega, Madison, USA) after 96 h of incubation. The concentration of either drug that gave half-maximal response (IC50) was
calculated using non-linear regression analysis. The data were ﬁtted to
a dose-response-inhibition equation (log [inhibitor] vs. normalized response curve).
2.11. Statistical analysis
The software GraphPad Prism version 6.00 (GraphPad Software
Inc., USA) was used for data and statistical analyses. Statistical analyses
were performed using unpaired Student’s t test, one-way analysis of
variance (ANOVA) followed by Bonferroni’s multiple comparison posttests, Kruskal-Wallis test followed by Dunn’s multiple comparison test
and two-way repeated ANOVA followed by Bonferroni’s multiple
comparison post-tests. For Fig. 1A, which has several time points and
groups, the experimental design was such that data were arranged as
follows: each row represented a diﬀerent time point and each column
represented a treatment group, so matched values were stacked into a
subcolumn. Based on this a repeated measures two-way ANOVA was
performed. This was followed by a post analysis for correction of
multiple comparisons with Bonferroni’s test (CIs and signiﬁcance were
3
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Fig. 1. Antihyperalgesic eﬀects of GYY4137against established paclitaxel-induced thermal hyperalgesia in female BALB/c mice is blocked by an ATP sensitive
potassium channel (KATP channel) inhibitor. (A) Eﬀect of treatment with GYY4137 and gabapentin on mice with paclitaxel-induced thermal hyperalgesia in a hotplate test. Reaction latencies (seconds) were recorded from baseline values (taken before and at day 7 after ﬁrst administration of paclitaxel) and at diﬀerent time
points following treatment with gabapentin (10 mg/kg), GYY4137 (25, 50 and 100 mg/kg), or their vehicles. Each bar represents the mean ± S.E.M (n = 6-8). *
p < 0.05, ** p < 0.01 compared to paclitaxel vehicle, # p < 0.05 compared to gabapentin at the same time point after treatment. (B) Eﬀect of treatment with
GYY4137 and glibenclamide, a KATP channel inhibitor, on mice with paclitaxel-induced thermal hyperalgesia in a hot-plate test. Reaction latencies (seconds) were
recorded from baseline values (taken before and at day 7 after ﬁrst administration of paclitaxel) and after 2 h following treatment with glibenclamide (10 mg/kg),
GYY4137 (50 mg/kg), combination of GYY4137 and glibenclamide, or their vehicles. Each bar represents the mean ± S.E.M. (n = 9). *** p < 0.001 compared to
drug vehicle, ### p < 0.001 compared to GYY4137-treated group.

prophylactic eﬀect of GYY4137.

GYY4137 is dependent, at least partly, on KATP channels.

3.3. Eﬀect of treatment with paclitaxel or paclitaxel plus GYY4137 on H2S
level in plasma and H2S generated by enzymes in tissues

3.2. Coadministration of paclitaxel with GYY4137 prevents the
development of paclitaxel-induced thermal hyperalgesia, cold allodynia and
mechanical allodynia

Plasma H2S levels were not diﬀerent in paclitaxel-treated group
compared to control (untreated) animals, but were signiﬁcantly increased in mice co-treated with paclitaxel plus GYY4137compared to
control animals or paclitaxel-treated group (p < 0.05; Fig. 3A) on day 7
after ﬁrst drug administration. H2S generated by enzymes in the brain
was similar in all the three groups i.e. control, paclitaxel-treated and
paclitaxel plus GYY4137 co-treated groups (p > 0.05; Fig. 3B) on day 7
after ﬁrst drug administration. On the other hand, H2S generated by
enzymes in the spinal cord and paw skin was signiﬁcantly lower in
paclitaxel-treated mice than in untreated control mice (p < 0.05;
Fig. 3C-D), and co-treatment with paclitaxel plus GYY4137signiﬁcantly
increased H2S generation compared to paclitaxel only-treated mice
(p < 0.05; Fig. 3C-D).

Mice treated with paclitaxel plus GYY4137 (50 mg/kg) had RTL
(8.22 ± 0.5 s, n = 10) similar to the vehicle-only treated control animals without hyperalgesia (9.29 ± 0.2 s, n = 8; p > 0.05; Fig. 3),
which were signiﬁcantly higher than those of the mice treated with
paclitaxel alone. As such, the RTL of the mice co-treated with paclitaxel
plus GYY4137 at 50 mg/kg for 5 consecutive days was signiﬁcantly
higher on day 7 after the ﬁrst drugs administration than those treated
with paclitaxel alone, i.e. with hyperalgesia (RTL 8.22 ± 0.5 vs.
5.67 ± 0.2 s, respectively, n = 10; p < 0.0001; Fig. 2A). Similar results
in mice co-treated with paclitaxel and GYY4137 (50 mg/kg) were observed following assessment of cold and mechanical allodynia (Fig. 2B
& C). In the cold plate test, the RTL of paclitaxel + GYY4137-treated
animals was signiﬁcantly higher compared to paclitaxel-treated animals
(RTL 50.09 ± 3.9 vs 26.04 ± 2.0 s, n = 8, respectively; p < 0.001;
Fig. 2B) and was similar to the vehicle-only treated group (RTL
55.86 ± 1.5 s, n = 8; p > 0.05; Fig. 2B). In a separate set of experiments, paclitaxel + GYY4137 treated animals showed signiﬁcantly
higher withdrawal threshold to mechanical stimuli than paclitaxeltreated mice (3.27 ± 0.07 g vs 1.82 ± 0.08 g, respectively; n = 8;
p < 0.001; Fig. 2C), but was similar to the vehicle-only treated group
(3.7 ± 0.1 g, n = 8; p > 0.05; Fig. 2C). These data show that the
concomitant treatment of paclitaxel with GYY4137 markedly prevented
the development of paclitaxel-induced thermal hyperalgesia as well as
cold and mechanical allodynia, thus indicating a preventive/

3.4. GYY4137 enhances the anti-proliferative eﬀects of paclitaxel
The exposure of cultured breast cancer MCF-7 cells to paclitaxel (1
nM to 100 μM) for 96 h caused concentration-dependent decrease in
tumor cell viability as assessed by MTT assay (p < 0.05; Fig. 4A). Paclitaxel inhibited MCF-7 cell proliferation by 40 % at 10 nM concentration which was increased to 50 % at concentrations ranging from
50 nM to 10 μM. At higher concentrations (50–100 μM) paclitaxel almost completely inhibited cell proliferation. The IC50 of paclitaxel was
80 nM. GYY4137 did not inhibit cell proliferation at concentrations
ranging from 1 nM to 50 μM, but signiﬁcantly inhibited (40 %) cell
4
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Fig. 2. Co-administration of GYY4137 with paclitaxel prevents the development of paclitaxel-induced thermal hyperalgesia, cold allodynia and mechanical allodynia
in female BALB/c mice. Eﬀect of co-administration of GYY4137 with paclitaxel on the development of (A) paclitaxel-induced thermal hyperalgesia in a hot-plate test,
(B) paclitaxel-induced cold allodynia in a cold-plate test and (C) paclitaxel-induced mechanical allodynia measured by a dynamic plantar aesthesiometer. Paclitaxel
(2 mg/kg) was administered for 5 days with vehicle or GYY4137 (50 mg/kg). Each bar represents the mean ± S.E.M (n = 8-12). *** p < 0.001 compared to vehicles
only group (without hyperalgesia/allodynia) at the same time point after treatment. ### p < 0.001 compared to mice treated with paclitaxel-induced hyperalgesia/
allodynia treated with vehicle.

proliferation at 100 μM concentration (p < 0.05; Fig. 4A). GYY4137
(100 μM) produced an antitumor eﬀect in MCF-7 cell line, in agreement
with previously published reports [18]. The IC50 of GYY4137 was 373
μM. The combination regimen of paclitaxel (50 nM) plus GYY4137 (100
μM) signiﬁcantly inhibited cell proliferation compared with monotherapy (Fig. 4B). GYY4137 increased the paclitaxel-induced decrease

of cell viability of this breast carcinoma cell line (Fig. 4B). The combination of GYY4137 (100 μM) plus paclitaxel (50 nM) decreased the
tumor cell proliferation signiﬁcantly much more that each individual
drug (p < 0.05; Fig. 4B). Thus, the combination of paclitaxel plus
GYY4137 does not negatively interfere with the anti-proliferative activity of paclitaxel in breast cancer cell line in vitro; rather, produces a

Fig. 3. Measurement of H2S level in control (untreated), paclitaxel-treated and paclitaxel and GYY4137 (50 mg/kg) co-treated mice at day 7 after ﬁrst administration
of paclitaxel. (A) Plasma H2S levels were not diﬀerent in paclitaxel group compared to control animals, but were signiﬁcantly increased with GYY4137 co-treatment
compared to both control (* p < 0.05) and paclitaxel only group (# p < 0.05). (B) Brain H2S enzymatic generation is similar in all the groups (p > 0.05). (C) Spinal
cord and (D) paw skin H2S enzymatic production in paclitaxel-treated mice is signiﬁcantly lower than untreated controls (* p < 0.05), and GYY4137 co-treatment
signiﬁcantly increased spinal cord H2S generation compared to paclitaxel only-treated mice (# p < 0.05). Bars represent mean ± S.E.M of 6-8 samples.
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Fig. 4. Eﬀects of monotherapy or combination regimen with paclitaxel or GYY on MCF-7 cell proliferation. Cells were seeded in a 24 well plate, allowed to attach
overnight and treated after 24 and 72 h with vehicle (solid bars) or various concentrations of (A) paclitaxel and GYY4137or (C) their combination. Growth was
assessed by MTT assay after 96 h of incubation. Each point or bar represents the mean ± SEM of 3 determinations. * p < 0.05 denote signiﬁcant diﬀerence from
vehicle-treated group (0 in ﬁgure A), # p < 0.05 denote signiﬁcant diﬀerence from paclitaxel monotherapy.

blocker glibenclamide. Co-administration of GYY4137 with paclitaxel
prevented the development of paclitaxel-induced thermal hyperalgesia,
cold allodynia and mechanical allodynia. Paclitaxel-treatment induced
a decrease in H2S generation by enzymes in the paw skin and spinal
cord, which was prevented by co-administration with GYY4137.
GYY4137 had some anti-proliferative eﬀects against a breast cancer cell
line MCF-7 and enhanced the anti-proliferative eﬀects of paclitaxel
against these cells.
The antihyperalgesic eﬀect of GYY4137 in mice with established
paclitaxel-induced thermal hyperalgesia was comparable to that of

positive additive anti-proliferative eﬀect.

4. Discussion
The ﬁndings of the present study suggest that the slow release H2S
donor GYY4137 has therapeutic potential and preventive role of in
CINP caused by paclitaxel in a murine model. GYY4137 produced an
acute antihyperalgesic eﬀect comparable to the anticonvulsant gabapentin, which is commonly used to relieve neuropathic pain. The antihyperalgesic eﬀect of GYY4137 was antagonized by the KATP channel
6
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properties of paclitaxel against the MCF-7 cell line. These results suggest that GYY4137 in addition to alleviation and prevention of paclitaxel-induced painful neuropathy it also enhances paclitaxel’s antiproliferative properties against a cancer cell line, and therefore may be
useful for the prevention and management of paclitaxel-induced painful
neuropathy.

gabapentin, although the highest dose of GYY4137 used (100 mg/kg)
produced a higher eﬀect at one-time point (3 h) and had an earlier
onset and longer duration of antihyperalgesic activity than gabapentin
from 1 to 4 h versus from 1.5 to 3 h, respectively. Gabapentin has been
reported to ameliorate several types of acute and chronic pain [22]
including diabetic neuropathic pain [23] and CINP [24–27]. The results
of the current study demonstrate that GYY4137 has antihyperalgesic
activities against paclitaxel-induced thermal hyperalgesia. GYY4137
and another H2S donor NaHS have also been shown to relieve cold
allodynia induced by another anticancer drug oxaliplatin in mice [13].
NaHS also relieved cold allodynia induced by paclitaxel in mice [13].
Hydrogen sulﬁde donors have been reported to alleviate other types of
neuropathic pain such as neuropathic pain in chronic constriction injured rats [10]. The activity of NaHS against oxaliplatin-induced coldallodynia was inhibited by the Kv7 potassium channel blocker XE991
[13], demonstrating a role of the voltage-gated Kv7potassium channels
in the antiallodynic eﬀect of H2S donors. There are many types of potassium channels that fall under four classes: calcium-activated potassium channels, inwardly rectifying potassium channels, tandem pore
domain potassium channels and voltage-gated potassium channels. The
involvement of potassium channels activation in mediating analgesia
has been demonstrated for several drugs, such as opioids [27], some
nonsteroidal anti-inﬂammatory drugs (NSAIDs) [28], and the antidepressants amitriptyline and clomipramine [29]. Previous studies in
inﬂammatory pain models showed that the H2S-releasing aspirin
(NOSH-aspirin) was superior to aspirin in reducing inﬂammatory pain
[30], possibly due to H2S inhibiting the production of pronociceptive
cytokines such as IL-1β, and directly blocking certain hyperalgesic
mediators in a mechanism dependent on modulation of KATP channels
[30]. Various studies have shown that H2S also produces its eﬀects via
activation of KATP channel, an inwardly rectifying potassium channel
[31]. In the current study, the antihyperalgesic activity of GYY4137
against paclitaxel-induced thermal hyperalgesia was blocked by the
KATP channel blocker glibenclamide, demonstrating a role of KATP
channel in the antiallodynic eﬀect of the H2S donor. A similar eﬀect was
also reported in the gastrointestinal tract as H2S was shown to exert
antinociceptive activity by activating KATP channels [32].
H2S levels and expression of the H2S-generating enzymes have been
found to be altered in plasma and tissues of animal models of various
diseases including atherosclerosis, diabetes, diabetic cardiomyopathy,
traumatic brain injury (TBI) etc. [33–37]. Thus, we determined H2S
level in the plasma, and the enzyme-mediated H2S generation in isolated brain, spinal cord and paw skin tissues from paclitaxel-treated
mice suﬀering from painful neuropathy to understand its possible implication in the pathogenesis of CINP. Mice with established paclitaxelinduced hyperalgesia and allodynia did not exhibit any change in
plasma H2S level or brain H2S generation, however spinal cord and paw
skin H2S generation was signiﬁcantly reduced. These ﬁndings suggest
that deﬁciency in H2S generation in both the central nervous system i.e.
spinal cord and the periphery i.e. paw skin might contribute to the
pathogenesis of paclitaxel-induced hyperalgesia and allodynia. Cotreatment with GYY4137 prevented the reduction in H2S generation
induced by paclitaxel as well as the paclitaxel-induced thermal hyperalgesia, cold allodynia and mechanical allodynia. This suggest that
prevention of chemotherapy-induced reduction in H2S generation using
H2S donors such as GYY4137 is a plausible therapeutic option for CINP.
This is similar to what has been reported in an animal model of TBI,
where using NaHS as an H2S donor protected against brain edema,
behavior deﬁcits and brain damage induced by TBI [38].
Paclitaxel is used as a chemotherapeutic drug and therefore it is
preferable that any drug used to alleviate its adverse eﬀects should not
negatively impact the anticancer eﬀect of paclitaxel. GYY4137 has been
reported to have anti-cancer activities both in vitro and in vivo
[21,39,40]. In the current study, GYY4137 also had anti-proliferative
activity against MCF-7, a breast cancer cell line, similar to what was
previously described [21]. GYY4137 enhanced the anti-proliferative

5. Conclusion
In conclusion, the results of the current study reveal for the ﬁrst
time that the slow-release H2S donor GYY4137 can both prevent the
development of paclitaxel-induced neuropathic pain (PINP) and alleviate established PINP, while enhancing paclitaxel’s anti-proliferative
properties against a cancer cell line. These ﬁndings support previous
reports demonstrating the ability of H2S to ameliorate allodynia and
hyperalgesia associated with other types of neuropathic pain in animal
models [9–12]. Deﬁciency in the generation of the endogenous H2S
seems to play a role in the pathogenesis of PINP. Further studies are
necessary to investigate the changes in H2S generating enzymes and
their possible contribution to PINP or CINP in general. GYY4137 and
possibly other slow-release H2S donors warrant further research as
potential drugs for prevention or alleviation of PINP in order to improve the outcomes and quality of life for patients receiving paclitaxel
as a chemotherapeutic drug.
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